Nerve growth factor (NGF) in the mouse submandibular gland undergoes cleavage of its amino-terminal octapeptide when salivation is induced by epinephrine. The significance of this event is uncertain; cleaved NGF demonstrates bioactivity and no function has been attributed to the octapeptide produced (NGF-OP; Ser-Ser-Thr-His-Pro-Val-PheHis). Enzyme inhibition studies indicating structural relatedness of NGF-OP and bradykinin (BK) prompted us to determine whether NGF-OP would elicit BK-like actions. We found that like BK, NGF-OP induced a decrease in mechanical nociceptive threshold (i.e., produced hyperalgesia) in the hairy skin of the rat. This effect was dose-dependent and sequence-specific; like BK it was attenuated by sympathectomy and indomethacin pretreatment. However, NGF-OP actions appeared to be distinct from those for BK in that tissue injury was required for NGF-OP to induce hyperalgesia. Furthermore, we found no evidence that NGF-OP bound to or activated BK receptors. Our data indicate that NGF-OP is a distinct mediator of hyperalgesia. We suggest that NGF-OP alters pain threshold in the i jured target regions of NGF-responsive neurons.
Nerve growth factor (NGF) is a polypeptide produced in the target regions ofresponsive neurons. In the peripheral nervous system, it is produced in tissues innervated by dorsal root ganglion sensory and sympathetic neurons. Through binding to specific receptors, NGF acts to encourage the survival and differentiation of young neurons and the maintenance of mature neurons (1) . NGF synthesis and release in target tissues thus appears to regulate their innervation (1) (2) (3) . NGF may have a role after nerve injury that is also made possible through synthesis in tissues intimately in contact with the neurites of responsive neurons (4) (5) (6) . Transection of the sciatic nerve leads to a marked increase in NGF gene expression in the proximal stump and distal segment. NGF mRNA is found in Schwann cells and other supporting cells (5) . Interleukin 1 release from macrophages infiltrating the lesion appears to enhance NGF gene expression (6, 7) . Provision of a local source of NGF in the proximal stump and distal segment may act to encourage nerve regeneration (2) . Indeed, the degeneration of axotomized sensory neurons, as determined by morphological, neurochemical, and neurophysiological measures, was prevented or reduced when exogenous NGF was administered to the proximal stump (8, 9) .
Though NGF production appears in many tissues to be directed at providing NGF to serve as a target-derived neurotrophic factor, it is unlikely that this is the case for all tissues. The mouse submandibular gland is a tissue where NGF production may serve a different role. Regulation of NGF levels in this gland is distinct from that in other innervated tissues in several respects. NGF levels are regulated by testosterone (10) . NGF content increases markedly at puberty and the level in males is 80-fold greater than that in females (11) . In males, NGF is present at concentrations about 106-fold those in typical targets (e.g., heart atrium and iris) (2, 11) . Importantly, however, the extraordinarily high NGF level in the submandibular gland is not associated with sympathetic innervation markedly denser than other peripheral tissues (12, 13) . Suggesting that mouse submandibular gland NGF is relatively unavailable to innervating sympathetic neurons are data showing that NGF levels in the superior cervical ganglion of male mice are only about 3-fold those in the rat, an animal in which relatively little NGF is produced in the submandibular gland (11, 14) . Moreover, the marked difference in submandibular gland NGF content between males and females is associated with only a modest difference in NGF levels in the superior cervical ganglion (11) . A remarkable feature of mouse submandibular gland NGF is that it is present in salivary gland secretions (15) ; indeed, most NGF present in the gland is secreted into saliva after administration of a-adrenergic agonists (16) . A clue to the biological role of submandibular gland NGF may be its secretion with other proteins produced in this tissue (17, 18) .
One such protein is P-NGF-endopeptidase (19) , an enzyme that removes the NGF amino-terminal octapeptide during secretion induced by epinephrine (17) . The physiological significance of this event is uncertain since no activity has been defined for the octapeptide produced (NGF-OP).
The studies reported herein detail an attempt to define an activity for NGF-OP. They were prompted by the following observations on P-NGF-endopeptidase. ( (ii) though it has few known substrates, the enzyme also cleaves mouse kininogen to release bradykinin (BK) (18) ; and (iii) BK, lysyl BK, and NGF-OP were each found to inhibit activity of the purified enzyme, suggesting that these peptides share one or more structural features (ref. 19 ; J.E.W. and W.C.M., unpublished observations). We asked whether the structural similarity of NGF-OP to BK would lead to similarity in actions in vivo. We examined a system in which BK actions were prominent, well-studied, and presumed to reflect a physiologically meaningful phenomenon involving NGF-responsive neurons. BK induces hyperalgesia, an enhanced sensitivity to pain thought to result from a decrease in the mechanical nociceptive threshold of the peripheral terminals of primary afferent nociceptors (21, 22) . Like BK, NGF-OP induced hyperalgesia; however, several features of the response distinguished NGF-OP actions from those of BK.
Abbreviations: NGF, nerve growth factor; NGF-OP, NGF aminoterminal octapeptide (Ser-Ser-Thr-His-Pro-Val-Phe-His); NGF-SOP, NGF-OP with amino acids in random sequence (Ser-Phe-ThrVal-Ser-His-His-Pro); BK, bradykinin; NE, norepinephrine; PGE2, prostaglandin E2; 6-keto-PGF1,, 6 -keto-prostaglandin Fl,,. (22) . Of note, the hyperalgesia induced by BK is different from that induced by NE in that BK acts in both normal skin and in skin previously traumatized by application of chloroform; NE is effective only in the latter (22) .
The following agents were tested for their ability to induce hyperalgesia: (i) NGF-OP (Ser-Ser-Thr-His-Pro-Val-PheHis; i.e., the amino-terminal octapeptide of NGF terminating either as the carboxylic acid or as the amide of the carboxylic acid), (ii) an octapeptide containing the same amino acids in random order (NGF-SOP; Ser-Phe-Thr-Val-Ser-His-HisPro; terminating as the carboxylic acid), (iii) the a-adrenergic antagonist phentolamine (Sigma), and (iv) mouse NGF prepared by ion-exchange chromatography and characterized as described (24) . By SDS/PAGE, =60% of mouse NGF chains were intact at the amino terminus (24) . NGF-OP and NGF-SOP were synthesized by solid-phase methods (25) The Randall-Selitto paw-withdrawal test was performed on 250-to 300-g male Sprague-Dawley rats (Bantin and Kingman, Fremont, CA). The nociceptive flexion reflex was quantified with a Ugo Basile analgesymeter (Stoelting). This device generates a mechanical force, increasing linearly with time, that is applied to the dorsum of the hindpaw. The nociceptive threshold is defined as the force, in grams, at which the rat withdraws its paw. During the week prior to gathering data, animals were trained in the device by applying the stimulus at 10-min intervals for 2 hr each day. This adaptation produces a stable baseline threshold measurement and enhances detectability of hyperalgesic effects. On the day of the experiment, the rats were exposed to the test stimulus at 5-min intervals for 2 hr prior to the measurement of baseline thresholds, which were defined as the mean of the last six determinations. Thereafter NGF-OP and NGF-SOP were examined in normal rats and in rats that had been pretreated topically with chloroform (Fisher Scientific) to induce local tissue injury (22) . When used, chloroform (50 Al) was applied for 90 sec/day for 2 days to the dorsum of the rats' hindpaws. This procedure has been shown to induce cutaneous hyperalgesia that is exacerbated by NE (22) . The chloroform-pretreated rats were otherwise subjected to the same experimental protocol as normal rats.
To study the contribution of sympathetic neurons to hyperalgesia, chemical sympathectomy was achieved by injecting 6-hydroxydopamine (Aldrich Chemical, Milwaukee) 50 mg/kg on days 1 and 2, 100 mg/kg on days 3 and 4, and 100 mg/kg on day 7, -12 hr prior to testing. This protocol is modified after one that causes a selective loss of innervation by sympathetic postganglionic neurons (26) and has been shown to abrogate the hyperalgesic response to BK in skin (22) . The cyclooxygenase inhibitor indomethacin (Sigma), when used, was dissolved in a vehicle of 2% (wt/vol) Na2CO3, titrated to pH 7.2 with NaH2PO4, and injected intraperitoneally at 2 mg/kg -30 min prior to testing (22) .
Studies to Determine Whether NGF-OP Acts at a BK Receptor. NGF-OP and NGF-SOP, both in the carboxylic acid form, were tested for their ability to bind and activate BK receptors. Assays of binding of 3H-labeled BK to guinea pig ileum were performed exactly as indicated (27) . Terminal ileum from male Hartley guinea pigs (150-350 g) was dissected, placed in 20 vol of buffer A (27) , homogenized, and centrifuged as described (27) . The final pellet was resuspended in buffer A containing bovine serum albumin (1 g/liter) (Sigma) and bacitracin (0.14 g/liter) (Sigma) to achieve a final concentration of 1 g of the original tissue (wet weight) per 170 ml (27) . In binding assays, 50 ,u of 3H-labeled BK (New England Nuclear; specific activity = 78 Ci/mmol; diluted in buffer A to achieve a final concentration of 0.2 nM) was incubated with 100 pu of buffer A containing the peptide to be used to displace 3H-labeled BK and 750 ,ul of tissue homogenate. Tubes in which no displacing peptide was present were used to measure maximum binding of 3H-labeled BK; nonspecific binding was measured in the presence of 1 ,uM BK (Bachem). Specific binding was 97% of total. NPC567 (D-Arg-[Hyp3,D-Phe7]BK); Hyp is hydroxyproline; Nova Pharmaceuticals, Baltimore, MD) was also used to displace BK binding. Incubations were for 90 min at ambient temperature. The assay mixture was passed through Whatman GF/B glass fiber filters that had been treated for 2 hr with polyethyleneimine (2 g/liter) (Sigma) in a Brandel tissue harvester (Gaithersburg, MD); filters were washed with four 1-ml vol of ice-cold 50 mM Tris-HCl (pH 7.4). Washed filters were dissolved in Ready-Safe Fluor (Beckman) for at least 90 min before radioactivity was measured by liquid scintillation spectrometry. Kd and Ki values were determined using EBDA (28) and LIGAND (29) software as indicated (22) .
BK and des-Arg9-BK (Bachem) were used to stimulate synthesis of arachidonate metabolites in Swiss 3T3 fibroblasts and in bovine pulmonary artery endothelial (CPAE) cells according to established methods (30) . Cells obtained from the American Type Culture Collection were maintained at 37°C in 10% C02/90% air in Dulbecco's modified Eagle's medium (DMEM) containing glucose (4.5 g/liter), 2 mM glutamine, penicillin (100 units/ml), and streptomycin (100 ,ug/ml). For Swiss 3T3 cells, 10% (vol/vol) calf serum was added; for CPAE cells, 10% fetal calf serum was added. Cultures at 50-80% confluence were taken for experiments. Prior to initiating these experiments, medium was aspirated from cells in 12-well plates and the wells were washed with 1 ml of serum-free DMEM containing 20 mM Hepes (pH 7.4; DMEM/Hepes). After aspiration of the wash, 0.5 ml of DMEM/Hepes containing the experimental agent was added. Swiss 3T3 cells were exposed for 5 min; CPAE cells were exposed for 3 min. For assays in which antagonism of BK actions was sought, peptides were included in the wash and cultures were then preincubated for 10 min prior to aspiration followed by addition of BK and the agent in DMEM/Hepes. After stimulation, medium was aspirated and frozen until a radioimmunoassay for prostaglandin E2 (PGE2) (Swiss 3T3 cells) or 6-keto-prostaglandin Fia (6-ketoPGFi,) (CPAE cells) by established methods (30) was done.
RESULTS NGF-OP Actions in Vivo. Intradermal injection of as little as 10 ng of BK into the hind paw of a normal rat produces a decrease in nociceptive threshold; the effect is dosedependent, pronounced, well-established within 5-10 min of presentation (21) , and continued for 90 min (31) . By using the same experimental conditions, injection of 1 Ag of NGF-OP failed to produce a significant effect on mechanical nociceptive threshold [F(3, 27) = 1.17; P > 0.05] (Fig. 1) . A different result was obtained in the paw injured by prior application of chloroform. In these rats NGF-OP administration elicited a dose-dependent decrease in threshold [F(3, 15) = 13.49; P < 0.001]. A significant change was apparent at 10 ng (P < 0.01 by Newman-Keuls post hoc comparison) and the maximal response was present at 100 ng (Fig. 1) . The potency of NGF-OP was similar to that for BK under these conditions (Y.O.T. and J.D.L., unpublished observations). After injection of NGF-OP, hyperalgesia was apparent by 10 min and persisted for >30 min (Fig. 2) . The amide form of NGF-OP also demonstrated activity, but only in the chloroform-treated paw, eliciting a dose-dependent decrease in threshold [F(3, 36) = 18.41; P < 0.001] that was apparent at 1 ng (P < 0.01 by Newman-Keuls post hoc comparison) and maximal at 100 ng. The time course of response was essentially the same as that shown in Fig. 2 . The effect ofNGF-OP was sequence specific; NGF-SOP, a randomly reordered form of the peptide, was without effect in normal paws [F(3, 21) = 1.38; P > 0.05] or in chloroform-treated paws [F(3, 15) = 0.90; P > 0.05] (Fig. 1) NGF-OP effects on the threshold for the nociceptive flexion reflex. The nociceptive threshold was examined 15 min after administration of test agent or vehicle and is shown as percent change from baseline (mean + SEM). There was no change in threshold due to vehicle injection. In normal skin, the intradermal injection of up to 1000 ng of NGF-OP (n = 10 paws) (o) or NGF-SOP (n = 8) (o) had no significant effect on nociceptive threshold. However, in chloroform-treated skin, NGF-OP (n = 6) (e) produced a dose-dependent decrease in nociceptive threshold that reached a plateau at 100 ng. The effect was sequence-specific since NGF-SOP (n = 6) (-) did not induce hyperalgesia. The carboxylic acid form of NGF-OP and NGF-SOP was used in these studies. (Fig.  3) . Even a dose 1000-fold greater than that which produced hyperalgesia in nonsympathectomized animals was without effect. NGF-OP also failed to produce hyperalgesia in indomethacin-pretreated rats [F(3, 36) = 1.16; P > 0.05].
To determine whether NGF-OP mediates its effect through altered adrenergic receptor binding or by inducing NE release, NGF-OP was administered to chloroform-treated paws after treatment with the a-adrenergic receptor antagonist phentolamine. NGF-OP-mediated hyperalgesia was not reduced by phentolamine pretreatment [F(3, 33) = 1.53; P > 0.05] (Fig. 3) .
NGF-OP Studies in Vitro. In inducing hyperalgesia that was dependent on the presence of sympathetic postganglionic neurons and blocked by inhibition of the cyclooxygenase pathway of arachidonic acid metabolism, NGF-OP actions -35- were similar to those of BK. However, the requirement for preceding trauma to demonstrate NGF-OP effects differentiated the two. Several possibilities can be envisioned to explain the difference. One is that NGF-OP and BK act through separate receptors. Another is that a separate class of BK receptors is induced by tissue injury, a suggestion for which there is precedent (32) . Yet another possibility was that NGF-OP binds to the BK receptor in normal and injured skin but is effective in activating them only in the injured state. In vitro studies offered a means to examine directly these possibilities.
The influence, or lack thereof, of NGF-OP on BK receptor binding and activation was examined. Two classes of BK receptors, referred to as BK1 and BK2, have been defined on the basis of differential sensitivity to synthetic BK analogs (33) . BK binds to guinea pig ileum through BK2 receptors (27, 33) . In binding experiments, 3H-labeled BK bound to ileal tissue homogenates with a Kd of 112 pM. Radiolabeled BK was displaced by NPC567, a BK2 antagonist, with a K1 of 24 nM. Even at concentrations up to 120 puM, NGF-OP and NGF-SOP failed to displace bound 3H-labeled BK [dpm bound (mean ± SEM) (n = 3): total 3H-labeled BK = 5768 + 28; 3H-labeled BK plus 1,pM NPC567 = 175 + 4; 3H-labeled BK plus 120,M NGF-OP = 5757 ± 6; 3H-labeled BK plus 120 /uM NGF-SOP = 5783 ± 17].
BK acts through the BK2 receptor to stimulate PGE2 synthesis in Swiss 3T3 fibroblasts (30) . The ED50 for the BK response in 3T3 cells was =500 pM (Fig. 4A) . (Fig. 4A) .
BK1 and BK2 receptors on bovine pulmonary artery endothelial cells (CPAE cells) mediate BK-induced synthesis of prostacyclin. The latter can be measured as an increase in the level of its metabolite 6-keto-PGFia, in culture supernatants (30) . The ED50 for BK is =0.3 nM (30). NGF-OP had no effect . DesArg9-BK is a BK1 agonist that induces prostacyclin synthesis in CPAE cells (30, 34) . The ED50 for des-Arg9-BK was =10 nM (Fig. 4B) . No measurable effect on des-Arg9-BK actions was seen with an NGF-OP (12 ,uM) pretreatment. DISCUSSION
We have shown that (i) NGF-OP induces hyperalgesia in a manner that is dose-dependent and sequence-specific; (ii) the NGF-OP effect is comparable in potency to indirectly acting hyperalgesic agents; (iii) the NGF-OP response is seen only in skin traumatized by prior chloroform treatment; (iv) NGF-OP-mediated hyperalgesia appears to be dependent on the presence of sympathetic innervation and production of prostaglandins; and (v) NGF-OP-induced hyperalgesia is distinct from that seen with either BK or NE. These results identify NGF-OP as a distinct indirect mediator of hyperalgesia. endopeptidase in which inhibition of enzyme activity was demonstrated for both NGF-OP and BK, suggesting that these peptides shared structural features (19) . They raised the possibility that NGF-OP and BK may act through the same or similar receptors to mediate similar physiological actions. Attention was focused on the activities of BK in the peripheral nervous system because of the role of NGF in supporting the growth, differentiation, and, to some extent, the maintenance of sensory and sympathetic neurons (1) .
In initiating these studies we expected that, like BK, NGF-OP might produce hyperalgesia in the rat paw. In one experimental paradigm, hyperalgesia did follow NGF-OP treatment. Like BK, the NGF-OP-induced decrease in nociceptive threshold was achieved with nanogram amounts, was dose-dependent, and required the presence of sympathetic innervation and prostaglandin synthesis. Distinctly unlike BK, however, NGF-OP was found to act only in skin injured by pretreatment with chloroform. In regard to the need for preceding trauma, NGF-OP actions were similar to those of NE (22) . The duration of the NGF-OP response was also similar to that seen with NE (31) . These data suggested that NGF-OP actions may be mediated by NE. However, failure to block NGF-OP effects with phentolamine indicates that NGF-OP does not act through NE release and that NE binding to a-adrenergic receptors is not a necessary component of the response. NGF-OP thus appears to act through a mechanism distinct from that for either BK or NE.
The dose dependency and stereospecificity of NGF-OPinduced hyperalgesia are evidence for a receptor. The findings recorded herein suggest that this receptor is distinct from the NGF receptor. Extensive consideration was directed at the possibility that NGF-OP acted through BK receptors. The NGF-OP effect was distinct from that for BK in the need for prior tissue injury, but these data did not rule out NGF-OP action through a BK receptor. Indeed, it was conceivable that a separate class of BK receptors was induced by tissue injury or that signal transduction due to NGF-OP binding to BK receptors was effected only in the injured state. In fact, we found no evidence that NGF-OP binds to or activates either BK1 or BK2 receptors. The cellular locus of NGF-OP action is unknown. However, the requirement for sympathetic innervation suggests that, like BK and NE (22) , NGF-OP may act on peripheral sympathetic nerve terminals. Hyperalgesia is, to our knowledge, the first biological response to be ascribed to NGF-OP. Earlier inability to detect NGF-OP activity (18, 35) was due to use of assays insensitive to its actions.
The physiological significance of NGF-OP production is uncertain. However, two possibilities can be envisioned. The first of these is suggested by the context in which NGF-OP is produced in vivo. Under natural conditions adult male mice fight with males of the same colony and will also fight in the laboratory if animals are held in isolation for several weeks before one male is paired with another in the same cage.
Fighting results in severe biting and even the death of one of the partners may result (36, 37) . Submandibular gland NGF stores are depleted when subjects fight (36) . Sympathetic discharge is a likely component of the fighting response; it has been shown that adrenergic stimulation elicits marked NGF release into saliva (16, 17) . A significant fraction (30%o) of NGF peptide chains are cleaved at the amino terminus as a result of adrenergically mediated salivation (17) , thus releasing rather large amounts of NGF-OP. It is likely that NGF-OP production occurs during secretion since NGF purified from the gland homogenate is largely intact at the amino terminus and essentially all NGF present in saliva is found in a molecular complex (7S NGF) that prevents its cleavage (17, 20) . It can be calculated that -3 ,ug of NGF-OP (or =2 .g/100 ILI) is liberated into the saliva of a single male mouse. If even a minority (25%) of NGF-OP remains intact, the amount present in 2 1.l, introduced into previously injured skin, would be sufficient to produce pain greater than that due to the bite itself. Conceivably, NGF-OP-induced hyperalgesia may modify further fighting behavior. Data for NGF-OP production and activity in vivo are consistent with a physiological role for this peptide.
Biochemical data suggests that NGF-OP actions may not be limited to the mouse. Of note, the sequence of this portion of NGF has been conserved. Thus, mouse and man differ in but two residues and these substitutions are conservative (39) . An additional physiological role for NGF-OP is suggested by the finding that hyperalgesia was induced only in injured skin. Tissue injury elicits inflammation (heat, redness, swelling, and pain). Kinins generated locally by the action of kallikrein enzymes contribute to inflammation (32, 33, 38) . It is possible that NGF produced in injured tissue normally contributes to the hyperalgesia by serving as substrate for a kallikrein present in this tissue. NGF-OP produced in this way would act locally to stimulate production and release of prostaglandins that would, in turn, act on nociceptive fibers to induce hyperalgesia. The latter may serve to limit further tissue injury by discouraging manipulation or use of the affected region. We failed to detect hyperalgesia after injecting NGF in the normal or injured paw, a result that could be taken as evidence against this hypothesis. However, it is not known that injecting NGF under the conditions used for these experiments would give it access to an enzyme that can act to produce NGF-OP. To test this hypothesis it will be important to show that NGF-OP is actually produced in injured or inflamed tissues and demonstrate the locus of its actions.
